Trajectories of the SARS-CoV-2 RNA load in patients with hematological malignancy.
COVID-19
SARS-CoV-2
virus shedding
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
revised:
15
03
2023
received:
11
01
2023
accepted:
20
03
2023
medline:
9
6
2023
pubmed:
26
3
2023
entrez:
25
3
2023
Statut:
ppublish
Résumé
The higher risk of prolonged viral shedding in coronavirus disease (COVID-19) patients with hematological malignancies (HM) necessitates test-based de-isolation strategies. However, evidence to establish their appropriate isolation period is insufficient. This study investigated the factors affecting prolonged viral shedding and the requisite isolation period in these patients. We retrospectively reviewed 14 COVID-19 patients with HM between January and April 2022, who were subjected to our test-based de-isolation strategy, followed by analysis of the viral load trajectory. The viral loads of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were evaluated using the cycle threshold (C The median interval between onset and attainment of a C The SARS-CoV-2 viral load trajectories in patients with HM can be stratified by treatment history for the underlying HM and severity of COVID-19.
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
57-62Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Prather KA, Wang CC, Schooley RT. Reducing transmission of SARS-CoV-2. Science. 2020;368:1422-1424.
Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg. 2020;78:185-193.
Centers for Disease Control and Prevention. Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic. Accessed October 2022. https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Fdisposition-hospitalized-patients.html
Alshukairi AN, Tolah AM, Dada A, et al. Test-based de-isolation in COVID-19 immunocompromised patients: cycle threshold value versus SARS-CoV-2 viral culture. Int J Infect Dis. 2021;108:112-115.
Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126:573-581.
Verdonck K, González E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis. 2007;7:266-281.
Kurokawa T, Hase M, Tokuman N, Yoshida T. Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab. Hematol Oncol. 2011;29:5-9.
Colucci M, Carsetti R, Cascioli S, et al. B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol. 2016;27:1811-1822.
Lee CY, Shah MK, Hoyos D, et al. Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies. Cancer Discov. 2022;12:62-73.
Tom MR, Mina MJ. To interpret the SARS-CoV-2 test, consider the cycle threshold value. Clin Infect Dis. 2020;71:2252-2254.
Mack CD, Wasserman EB, Killerby ME, et al. Results from a test-to-release from isolation strategy among fully vaccinated National Football League Players and staff members with COVID-19 - United States, December 14-19, 2021. MMWR Morb Mortal Wkly Rep. 2022;71:299-305.
Kapoor M, Kalita D, Panda PK. Cycle threshold values versus reverse transcription-polymerase chain reaction positivity in COVID-19 de-isolation. Ind J Med Microbiol. 2021;39:133-135.
National Institute of Infectious Diseases. Most Recent Infection Status, etc., of COVID-19 (as of February 16, 2022; Available in Japanese). Accessed October 2022. https://www.niid.go.jp/niid/ja/2019-ncov/10970-covid19-ab72th.html
The National Institutes of Health. Clinical Spectrum of SARS-CoV-2 Infection. Accessed October 2022. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/
Duléry R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96:934-944.
He W, Chen L, Chen L, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34:1637-1645.
Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383:2586-2588.
Yasuda H, Mori Y, Chiba A, et al. Resolution of one-year persisting COVID-19 pneumonia and development of immune thrombocytopenia in a follicular lymphoma patient with preceding rituximab maintenance therapy: a follow-up report and literature review of cases with prolonged infections. Clin Lymphoma Myeloma Leuk. 2021;21:e810-e816.
Betrains A, Godinas L, Woei-A-Jin FJSH, et al. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J Haematol. 2021;192:1100-1105.
Baang JH, Smith C, Mirabelli C, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021;223:23-27.
Nakajima Y, Ogai A, Furukawa K, et al. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother. 2021;27:387-389.
Sepulcri C, Dentone C, Mikulska M, et al. The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient-A case study. Open forum. Infect Dis. 2021;8:ofab217.
Young BE, Ong SWX, Ng LFP, et al. Dynamics and immune correlates of coronavirus disease 2019 (COVID-19) severity. Clin Infect Dis. 2021;73:e2932-e2942.
Edelstein S, Sudri M, Tanous S, et al. Cycle threshold responses in SARS-COV2 PCR tests depend on the method by which the samples were obtained and require strict global standardization. Infection. 2022;50:959-963.
Rhoads D, Peaper DR, She RC, et al. College of American Pathologists (CAP) microbiology committee perspective: caution must Be used in interpreting the cycle threshold (Ct) value. Clin Infect Dis. 2021;72:e685-e686.